Photo of Vinay Prasad, MD, MPH

Vinay Prasad MD, MPH

Dr. Prasad specializes in caring for patients with hematologic malignancies, including Non-Hodgkin’s and Hodgkin’s lymphoma, chronic lymphocytic leukemia/lymphoma, mantle cell lymphoma and follicular lymphoma among others. He has advanced training in hematology (diseases of the blood and bone marrow) and oncology (cancer).  At OHSU, he is part of the lymphoma team, where he specializes in the care of people with hematologic malignancies, using chemotherapy, biological therapies, targeted therapies and immunotherapy to improve their health.

Dr. Prasad is nationally known for his research that seeks to improve the medical decisions doctors make, and improve the quality of evidence that doctors use to treat patients. He enjoys working with patients and their families to develop personalized treatment plans, and guide them through their care.  Dr. Prasad is the author of Ending Medical Reversal: Improving Outcomes, Saving Lives.

In his spare time, Dr. Prasad is an avid cyclist. He enjoys basketball, tennis, reading, gardening and occasionally binge-watching television.

Read more

Education

  • M.D., University of Chicago 2009
  • M.P.H., Johns Hopkins University 2014
  • Residency:

    • Internal Medicine, Northwestern University, 2012
  • Fellowship:

    • Oncology, National Cancer Institute; Hematology, National Heart Lung Blood Institute, 2015
  • Certifications:

    • American Board of Internal Medicine (Internal Medicine) 2012; Medical Oncology and Hematology (2015)

Memberships and associations

  • American Society of Clinical Oncology

Publications

  • "A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature." European Journal of Cancer  In: , Vol. 101, 01.09.2018, p. 143-151.
  • "A pooled analysis of published, basket trials in cancer medicine." European Journal of Cancer  In: , Vol. 101, 01.09.2018, p. 244-250.
  • "Why is research in early-stage cancer research so low?" Journal of Cancer Policy  In: , Vol. 17, 01.09.2018, p. 4-8.
  • "Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology." JAMA Oncology  In: , Vol. 4, No. 8, 01.08.2018, p. 1093-1098.
  • "Inconsistent reporting of potential conflicts of interest." JAMA - Journal of the American Medical Association  In: , Vol. 320, No. 4, 24.07.2018.
  • "Cost-effectiveness of nusinersen for spinal muscular atrophy : Reply." JAMA Pediatrics  In: , Vol. 172, No. 7, 01.07.2018, p. 701-702.
  • "Total costs of chimeric antigen receptor T-cell immunotherapy." JAMA oncology In: , Vol. 4, No. 7, 01.07.2018, p. 994-996.
  • "Direct-to-consumer genetic testing the implications of the US FDA's first marketing authorization for BRCA mutation testing." JAMA - Journal of the American Medical Association  In: , Vol. 319, No. 23, 19.06.2018, p. 2377-2378.
  • "If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis." Journal of General Internal Medicine  In: , 04.06.2018, p. 1-2.
  • "The US Food and Drug Administration's use of pathologic complete response as regulatory endpoint : Did it pay off?" Journal of Cancer Policy  In: , Vol. 16, 01.06.2018, p. 49-51.
  • "Concerns about the approval of nusinersen sodium by the US food and drug administration." JAMA Internal Medicine In: , Vol. 178, No. 6, 01.06.2018, p. 743-744.
  • "Low-value approvals and high prices might incentivize ineffective drug development." Nature Reviews Clinical Oncology  In: , 14.05.2018, p. 1-2.
  • "When is crossover desirable in cancer drug trials and when is it problematic?" Annals of Oncology In: , Vol. 29, No. 5, 01.05.2018.
  • "In reply." JAMA Internal Medicine  In: , Vol. 178, No. 4, 01.04.2018, p. 588-589.
  • "In reply." JAMA oncology  In: , Vol. 4, No. 4, 01.04.2018, p. 586-587.
  • "Crossover is not associated with faster trial accrual." Annals of Oncology In: , Vol. 29, No. 3, mdx821, 01.03.2018, p. 776-777.
  • "Without randomized studies, the costeffectiveness of a therapy cannot be known." Annals of Oncology In: , Vol. 29, No. 3, 01.03.2018, p. 527-529.
  • "PFO closure for secondary stroke prevention : is the discussion closed?" Journal of Thrombosis and Thrombolysis In: , 20.02.2018, p. 1-3.
  • "Nusinersen for spinal muscular atrophy are we paying too much for too little?" JAMA Pediatrics  In: , Vol. 172, No. 2, 01.02.2018, p. 123-125.
  • "Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it." Annals of Oncology In: , Vol. 29, No. 2, 01.02.2018, p. 298-300.
  • "Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers." JAMA oncology  In: , Vol. 4, No. 2, 01.02.2018, p. 157-158.
  • "Tisagenlecleucel - The first approved CAR-T-cell therapy : Implications for payers and policy makers." Nature Reviews Clinical Oncology  In: , Vol. 15, No. 1, 01.01.2018, p. 11-12.
  • "Pemetrexed in nonsquamous non-small-cell lung cancer : The billion dollar subgroup analysis." JAMA oncology  In: , Vol. 4, No. 1, 01.01.2018, p. 17-18.
  • "Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration : Retrospective observational study." BMJ (Online)  In: , Vol. 360, k668, 01.01.2018.
  • "Use of word “unprecedented” in the media coverage of cancer drugs : Do “unprecedented” drugs live up to the hype?" Journal of Cancer Policy  In: , Vol. 14, 01.12.2017, p. 16-20.
  • "Time from US Food and Drug Administration approval to publication of data for cancer drugs : A comparison of first and subsequent approvals." Blood Cancer Journal  In: , Vol. 7, No. 12, 41408, 01.12.2017.
  • "Clinically meaningful benefit : Real world use compared against the American and European guidelines." Blood Cancer Journal  In: , Vol. 7, No. 12, 645, 01.12.2017.
  • "Health policy : Me-too drugs with limited benefits-the tale of regorafenib for HCC." Nature Reviews Clinical Oncology  In: , Vol. 14, No. 11, 01.11.2017, p. 653-654.
  • "Research and development spending to bring a single cancer drug to market and revenues after approval." JAMA Internal Medicine  In: , Vol. 177, No. 11, 01.11.2017, p. 1569-1575.
  • "In reply." JAMA oncology  In: , Vol. 3, No. 11, 01.11.2017, p. 1588-1589.

Additional information

Edit profile